Pharmaceutical Sales and Marketing Articles

Pharmaceutical Sales Career In Pakistan

Submitted by Mariam Khan on Fri, 09/28/2012 - 00:37

News on Pharmaceutical sales career in Pakistan

Pharmaceutical sales career in Pakistan is a great opportunity. Pakistan is a growing market for this industry and it is still in the development phase. It is considered a young industry as compared to the international pharmaceutical industries. If you want to make a pharmaceutical sales career here, it is going to be a great option. As the industry is in the growth phase, many of the international and local companies are setting up here and they account for a fair number of job openings in the market.

Articles: 
Pharmaceutical Sales and Marketing Articles

Qualification For Pharmaceutical Sales Job

Submitted by Mariam Khan on Thu, 09/20/2012 - 17:45

Pharmaceutical sales job has become a hot cake for everyone. It is definitely a great career option but let me tell you; it is not for everyone. The nature of this job is such that it requires the best candidates to take these positions. Don't make any assumptions before you finish reading this post. I am going to tell you something about the requirement of employers for this particular position of pharmaceutical sales representative in different countries.

Articles: 
Pharmaceutical Sales and Marketing Articles

Pharmaceutical Sales Career In India

Submitted by Mariam Khan on Tue, 09/18/2012 - 16:55

Information on Pharmaceutical Sales Career In India

There is good news for those who want to know about pharmaceutical sales career in India. As you know, pharmacy has become one among the top industries in the world. The situation is much better in India where it is the fourth largest industry with many great career options. The performance of this industry has been remarkable in the past few years with a growth rate of 14 percent for the past 5 years. The industry is at the growth stage and represents a good opportunity to the international firms.

Articles: 
Pharmaceutical Sales and Marketing Articles

Pharmaceutical Sales Career In Canada

Submitted by Mariam Khan on Wed, 09/12/2012 - 12:40

If you are looking forward to a pharmaceutical sales career in Canada, have a look at the industry and its performance first. Well, let me share some findings from my research about this industry and you will find these helpful. According to a recent survey, the Canadian pharmaceutical industry is the 8th largest pharmacy industry in the world. It accounts for around 2.8 percent of the global pharmacy sales. The forecasts represent a positive growth in the industry as well as the number of job openings.

Articles: 
Pharmaceutical Sales and Marketing Articles

Pharmaceutical Sales Career in USA

Submitted by Mariam Khan on Tue, 09/11/2012 - 12:19

Pharmaceutical sales career in USA

Pharmaceutical sales career is still among the top five in the USA in terms of desirability. The reasons for this liking are many. People find this career option as the best as they see a phenomenal growth in this industry over the past years. If you are looking forward to make a career in this industry, let me share some information with you based on my research about the pharmaceutical industry. Pharmaceutical sales career in USA is considered safe and rewarding.

Articles: 
Pharmaceutical Sales and Marketing Articles

Should I Choose Pharmaceutical Sales as Career

Submitted by Mariam Khan on Sat, 08/18/2012 - 00:24

Pharmaceutical Sales as a Career : The Good and The Bad

If you have decided to make a move into the most rewarding pharmaceutical sales career, I feel happy for you. I have been following this great career option for long and have found it a satisfying and worth consideration option for many people. But there is something I want to discuss with you. Like every career, pharmaceutical sales option also has some advantages and disadvantages. Before discussing the pros and cons of pharmaceutical sales in detail, let me tell you something.

Articles: 
Pharmaceutical Sales and Marketing Articles

Pharmaceutical Sales

Submitted by Mariam Khan on Fri, 08/17/2012 - 23:57

What Are Pharmaceutical Sales After All?

When people talk about great career options, pharmaceutical sales career is placed in the top five. You must be wondering what these pharmaceutical sales are? After all, you need to know about the job before considering it as a career choice. Let me first define the pharmaceutical sales. It is the delivery of medicines developed with extensive research to the potential customers and this is carried out by the company's sales staff.

Articles: 
Pharmaceutical Sales and Marketing Articles

Politics & PDUFA

Everyone is preparing for a bumpy ride this year in Washington. The conventional wisdom is that President Obama has a year to enact new legislation before the political infighting becomes even more intense leading up to the 2012 presidential election. But the political tensions created by last November's mid-term elections make gridlock more likely. Congressional Republicans will seek to cut the federal deficit by squeezing budgets at government agencies.
Journal: 
Pharmaceutical Executive, Jan 1, 2011
Full Article Link: 
Click Here
Articles: 
Pharmaceutical Sales and Marketing Articles

The Right Mix for 2011

Digital has taken hold, mobile is growing rapidly, and print continues as a standard for marketing initiatives. So you might be asking yourself, which of these channels offers the most benefit, greatest reach, and best ROI? The answer is all of the above. But the challenge is in integrating them for greater impact. Eric Boothe
Journal: 
Pharmaceutical Executive, Jan 1, 2011
Full Article Link: 
Click Here
Articles: 
Pharmaceutical Sales and Marketing Articles

The Night Stalkers

As noted in our cover story this month, the consensus is that 2011 will be a tough year for pharma. It must confront the biggest breaking wave of patent expirations, while fiscal retrenchment has created an innovation cycle in reverse, as payers find new ways to curb the drugs bill. Risk-averse regulators are transforming old tools such as the FDA "complete response letter" into a registration parking lot, with no exit ramp to connect companies to a distracted--and increasingly impatient--community of clinicians and consumers.
Journal: 
Pharmaceutical Executive, Jan 1, 2011
Full Article Link: 
Click Here
Articles: 
Pharmaceutical Sales and Marketing Articles

The Steep, Slow Climb

"2011 will be the year of pharma making it over history's steepest patent cliff--or not. A few companies will fall behind in a way that will make it impossible for mergers to get them out," the head of a venture capital (VC) firm warns darkly, asking not to be named. Peter Tollman, Boston Consulting Group
Journal: 
Pharmaceutical Executive, Jan 1, 2011
Full Article Link: 
Click Here
Articles: 
Pharmaceutical Sales and Marketing Articles

The San Diego Story

Biotechnology is now a global industry, but success still requires that elusive mix of localized, clustered assets incorporating money, know-how, and a business culture that tolerates risk. Two years ago, Pharm Exec visited San Diego to identify what makes that region work as a locus for risky investments in the big ideas that lead to biotech breakthroughs ("San Diego's BioCluster by the Sea," May 2008).
Journal: 
Pharmaceutical Executive, Jan 1, 2011
Full Article Link: 
Click Here
Articles: 
Pharmaceutical Sales and Marketing Articles

In Through the Out Door

The end of another year is an appropriate time to highlight the march of time--and the transitions that accompany it. This broad theme of passage helps bind our editorial offerings this month, in which we present the valedictory musings of one of the world's leading drug regulators as well as our annual update on the state of circulation in pharma's drug pipeline. We round things off with a profile of key market trends in China.
Journal: 
Pharmaceutical Executive, Dec 1, 2010
Full Article Link: 
Click Here
Articles: 
Pharmaceutical Sales and Marketing Articles

Adherence Equation: The Code is Cracked!

Previously in Pharm Exec, we discussed the two basic roadblocks to effective problem solving in advancing the goals of patient adherence programs: 1) failure to define the problem at base; and 2) looking for the solution in the wrong place. This month, let's take a deeper look into the solution and how we can capture it so the organization can proceed to solve the problem around a set of tangible actions.
Journal: 
Pharmaceutical Executive, Dec 1, 2010
Full Article Link: 
Click Here
Articles: 
Pharmaceutical Sales and Marketing Articles

Emerging Stakeholders with Clout: The Press Power Behind ProPublica

ProPublica calls itself "an independent, non-profit newsroom that produces investigative journalism in the public interest." The organization's website touts the importance of focusing on stories with "moral force." The group, based in New York, began publishing in 2008 with an annual program budget of $10 million and a full-time staff of 32 reporters and editors, including such media bigwigs as Paul Steiger, former managing editor, and Richard Tofel, former assistant publisher, both of The Wall Street Journal, and Stephen Engelberg, ex-investigative editor of The New York Times.
Journal: 
Pharmaceutical Executive, Dec 1, 2010
Full Article Link: 
Click Here
Articles: 
Pharmaceutical Sales and Marketing Articles

A New Twist in the Cost Curve

On Sept. 17, the FDA and CMS jointly issued a Federal Register (FR) notice that they were establishing a process for overlapping evaluations of premarket, FDA-regulated medical products when the product sponsor and both agencies agreed to such parallel review. The notice also announced their intent to create a pilot program for parallel review of medical devices.
Journal: 
Pharmaceutical Executive, Dec 1, 2010
Full Article Link: 
Click Here
Articles: 
Pharmaceutical Sales and Marketing Articles

New Ballgame in Washington

The Republican wave that swept many long-standing Democrats out of Congress and state houses last month raises new challenges for pharma. While the slow pace of economic recovery and continued high unemployment were the top issues stirring voter discontent, healthcare reform emerged as a deciding factor as unhappy Americans went to the polls.
Journal: 
Pharmaceutical Executive, Dec 1, 2010
Full Article Link: 
Click Here
Articles: 
Pharmaceutical Sales and Marketing Articles

Is Euroland Following the US Disclosure Lead?

Making sense of the promotional spend and anti-corruption compliance burden is emerging as a key strategic issue for pharma--not just in the US but in the global market space as well, where regulatory safeguards are still porous. New survey research published by Cegedim Relationship Management documents this trend with a focused review of the growing pressure in Europe to follow the US with demands for a full tracking of how, where, and when pharma companies seek to influence the prescribing behavior of physicians and other healthcare practitioners.
Journal: 
Pharmaceutical Executive, Dec 1, 2010
Full Article Link: 
Click Here
Articles: 
Pharmaceutical Sales and Marketing Articles

Rheumatoid Arthritis: JAKing Down Inflammation

In the race to market the first oral drug to compete with high-priced injectables for rheumatoid arthritis (RA), Pfizer's tasocitinib has the home-stretch lead over Rigel, Vertex, and Incyte. All four contenders are Janus-associated kinase (JAK) inhibitors, a new class of molecules with anti-inflammatory activity that puts the brakes on RA's joint destruction. In a 600-patient Phase III trial, Pfizer's twice-daily anti-JAK pill reached two of three of its goals, reducing symptoms and increasing functionality, but failing to best placebo in number of remissions.
Journal: 
Pharmaceutical Executive, Dec 1, 2010
Full Article Link: 
Click Here
Articles: 
Pharmaceutical Sales and Marketing Articles

Depression: A Not-So-Rosy Outlook

"Depression is going through a challenging time," says Datamonitor analyst Ben Greenacre. "It's a mature market and reaching the patent cliff." Led by Prozac and Effexor, the market has been flooded with molecules that treat depression and anxiety by targeting two neurotransmitters, serotonin and norepinephrine. French pharma Servier took a very different approach with Valdoxan, a dual action molecule that combines a melanotergic receptor agonist and a 5HT2C antagonist, targeting the neurotransmitters dopamine and noradrenaline.
Journal: 
Pharmaceutical Executive, Dec 1, 2010
Full Article Link: 
Click Here
Articles: 
Pharmaceutical Sales and Marketing Articles

The Sum of All His Parts: Career Reflections of Europe's Chief Drug Regulator

The European Medicines Agency (EMA) is a unique institution, pursuing a mandate shared with a complex web of national and regional groups, each able to place a distinctive imprint around the delicate task of certifying the safety and efficacy of new drugs. In return, the EMA has made a virtue of necessity. It filled the regulatory space opened by the relentless progress of science and new information technologies to gradually expand its remit in a way that has maintained consensus among stakeholders.
Journal: 
Pharmaceutical Executive, Dec 1, 2010
Full Article Link: 
Click Here
Articles: 
Pharmaceutical Sales and Marketing Articles

Alzheimer's: A Disease at a Crossroads

"Alzheimer's is the black hole of R&D," says Wolters Kluwer's Ben Weintraub. "It's the only big disease left that is basically untreatable." Since 2003, more than 10 much-hyped compounds have bitten the dust. Almost all targeted the protein amyloid-beta, the hallmark plaque long thought to cause the disease's devastation of brain matter. But experimental agents that slow or stop the amyloid buildup have stubbornly shown no cognitive or memory benefit in patients.
Journal: 
Pharmaceutical Executive, Dec 1, 2010
Full Article Link: 
Click Here
Articles: 
Pharmaceutical Sales and Marketing Articles

The Next Wave: Pharm Exec's 2011 Pipeline Report

Like a mermaid or a minotaur, pharma's 2011 pipeline is a shape-shifting creature--a hybrid of primary care and specialty products; mass-market molecules and orphan-disease biologics; novel vaccines for neglected diseases that may save hundreds of thousands of lives at cost; and follow-on oncologics that may add a few months of survival with six-digit price tags for the few who can afford them. New forms of pharma life are rising out of the defunct blockbuster model, but they remain in morphing mode.
Journal: 
Pharmaceutical Executive, Dec 1, 2010
Full Article Link: 
Click Here
Articles: 
Pharmaceutical Sales and Marketing Articles